All In Biotech

Drug Trial Radar · NCT07503444

A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome

A Phase 3 Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study With Open-Label Extension to Evaluate the Efficacy And Safety of Fenfluramine Hydrochloride in Study Participants With Rett Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jul 14, 2026

Primary completion

Feb 6, 2029

Study completion Aug 29, 2031

Sponsor

Lead sponsor
UCB BIOSCIENCES, Inc.UCB
Sponsor type
Industry
First posted
Mar 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the efficacy of fenfluramine hydrochloride (HCl) versus placebo in study participants with Rett syndrome (RTT).

Conditions

  • Rett Syndrome

Interventions

  • fenfluramine hydrochlorideDrug

    Oral solution

  • PlaceboOther

    Oral solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline to Week 14 in Rett Syndrome Behaviour Questionnaire (RSBQ) Total ScoreTime frame: From Baseline (Day 1) to Week 14
  2. Clinical Global Impression of Change (CGIC) Score at Week 14Time frame: At Week 14

Locations

46 sites in 13 countries. Site status is shown where the registry gives one.

  • Ep0247 21010

    Little Rock, Arkansas · Recruiting

  • Ep0247 21009

    Miami, Florida · Recruiting

  • Ep0247 21011

    Orlando, Florida · Recruiting

  • Ep0247 21007

    Atlanta, Georgia · Recruiting

  • Ep0247 21003

    Philadelphia, Pennsylvania · Recruiting

  • Ep0247 21005

    Houston, Texas · Recruiting

  • Ep0247 21013

    Irving, Texas · Recruiting

  • Ep0247 21004

    Seattle, Washington · Recruiting

  • Ep0247 11001

    Brussels, Belgium · Recruiting

  • Ep0247 11002

    Edegem, Belgium · Recruiting

  • Ep0247 42001

    Beijing, China · Recruiting

  • Ep0247 42009

    Shanghai, China · Recruiting

  • Ep0247 12005

    Brest, France · Recruiting

  • Ep0247 12003

    Bron, France · Recruiting

  • Ep0247 12004

    Marseille, France · Recruiting

  • Ep0247 12001

    Paris, France · Recruiting

  • Ep0247 12006

    Paris, France · Recruiting

  • Ep0247 13001

    Tbilisi, Georgia · Recruiting

  • Ep0247 13002

    Tbilisi, Georgia · Recruiting

  • Ep0247 14001

    Vogtareuth, Germany · Recruiting

  • Ep0247 15001

    Budapest, Hungary · Recruiting

  • Ep0247 15002

    Debrecen, Hungary · Recruiting

  • Ep0247 16001

    Ramat Gan, Israel · Recruiting

  • Ep0247 17007

    Florence, Italy · Recruiting

  • Ep0247 17003

    Genova, Italy · Recruiting

  • Ep0247 17001

    Milan, Italy · Recruiting

  • Ep0247 17008

    Naples, Italy · Recruiting

  • Ep0247 17002

    Pisa, Italy · Recruiting

  • Ep0247 17009

    Roma, Italy · Recruiting

  • Ep0247 17006

    Troina, Italy · Recruiting

  • Ep0247 43005

    Chiyoda-ku, Japan · Recruiting

  • Ep0247 43004

    Kodaira, Japan · Recruiting

  • Ep0247 43001

    Kurume, Japan · Recruiting

  • Ep0247 43006

    Musashimurayama-shi, Japan · Recruiting

  • Ep0247 43002

    Osaka, Japan · Recruiting

  • Ep0247 43003

    Setagaya-ku, Japan · Recruiting

  • Ep0247 19003

    Gdansk, Poland · Recruiting

  • Ep0247 19002

    Krakow, Poland · Recruiting

  • Ep0247 11106

    Barcelona, Spain · Recruiting

  • Ep0247 11101

    Madrid, Spain · Recruiting

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.